NYSEAMERICAN:IMUC - Immunocellular Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.26 -0.01 (-3.70 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$0.27
Today's Range$0.26 - $0.27
52-Week Range$0.03 - $2.79
Volume160,900 shs
Average Volume1.13 million shs
Market Capitalization$8.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67

About Immunocellular Therapeutics (NYSEAMERICAN:IMUC)

Immunocellular Therapeutics logoImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.

Receive IMUC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSEAMERICAN:IMUC
CUSIP45253610
Phone+1-818-2642300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-270.08%

Miscellaneous

EmployeesN/A
Outstanding Shares41,930,000

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) Frequently Asked Questions

What is Immunocellular Therapeutics' stock symbol?

Immunocellular Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IMUC."

How were Immunocellular Therapeutics' earnings last quarter?

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) announced its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. View Immunocellular Therapeutics' Earnings History.

Are investors shorting Immunocellular Therapeutics?

Immunocellular Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 3,133,932 shares, a drop of 4.5% from the April 30th total of 3,281,161 shares. Based on an average trading volume of 559,678 shares, the short-interest ratio is currently 5.6 days. Currently, 7.5% of the company's stock are short sold.

Who are some of Immunocellular Therapeutics' key competitors?

Who are Immunocellular Therapeutics' key executives?

Immunocellular Therapeutics' management team includes the folowing people:
  • Mr. Gary S. Titus, Chairman & Corp. Sec. (Age 58)
  • Dr. Anthony J. Gringeri Ph.D., CEO, Pres & Director (Age 65)
  • Dr. John S. Yu M.D., Ph.D., Founder & Director (Age 54)
  • Mr. David E. Fractor CPA, Chief Financial Officer (Age 58)
  • Dr. Steven J. Swanson M.D., Ph.D., Sr. VP of Research (Age 62)

Has Immunocellular Therapeutics been receiving favorable news coverage?

News coverage about IMUC stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immunocellular Therapeutics earned a media sentiment score of 0.14 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.39 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Immunocellular Therapeutics?

Shares of IMUC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunocellular Therapeutics' stock price today?

One share of IMUC stock can currently be purchased for approximately $0.26.

How big of a company is Immunocellular Therapeutics?

Immunocellular Therapeutics has a market capitalization of $8.07 million.

How can I contact Immunocellular Therapeutics?

Immunocellular Therapeutics' mailing address is 30721 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7383, United States. The biotechnology company can be reached via phone at +1-818-2642300.


MarketBeat Community Rating for Immunocellular Therapeutics (IMUC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Immunocellular Therapeutics and other stocks. Vote "Outperform" if you believe IMUC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMUC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Immunocellular Therapeutics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) Consensus Price Target History

Price Target History for Immunocellular Therapeutics (NYSEAMERICAN:IMUC)

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/24/2017Maxim GroupReiterated RatingHoldView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) Earnings History and Estimates Chart

Earnings by Quarter for Immunocellular Therapeutics (NYSEAMERICAN:IMUC)

Immunocellular Therapeutics (NYSEAMERICAN IMUC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q1 2018($0.02)ViewN/AView Earnings Details
11/21/2017Q3 2017($0.40)ViewN/AView Earnings Details
8/14/2017Q2 2017($1.02)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.64)ViewN/AView Earnings Details
11/10/2016Q316($0.04)($0.04)ViewN/AView Earnings Details
8/22/2016Q2($0.07)($0.06)ViewListenView Earnings Details
5/12/2016Q116($0.07)($0.06)ViewListenView Earnings Details
3/30/2016Q415($0.06)($0.05)ViewListenView Earnings Details
11/10/2015Q315($0.06)($0.04)ViewN/AView Earnings Details
8/6/2015Q215($0.05)($0.03)ViewN/AView Earnings Details
5/11/2015Q1($0.02)($0.02)ViewN/AView Earnings Details
3/9/2015Q414($0.05)($0.04)ViewN/AView Earnings Details
11/10/2014Q314($0.06)($0.03)ViewN/AView Earnings Details
8/11/2014($0.06)($0.04)ViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.05)ViewN/AView Earnings Details
11/6/2013Q3 2013($4.00)($2.00)ViewN/AView Earnings Details
8/7/2013Q2 2013($2.40)($1.60)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.08)($0.05)ViewN/AView Earnings Details
3/5/2013Q4 2012($0.08)$0.01ViewN/AView Earnings Details
11/12/2012Q312($0.02)ViewN/AView Earnings Details
8/15/2012Q2 2012($3.60)($3.12)ViewN/AView Earnings Details
5/11/2012Q1 2012($3.20)($3.68)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Immunocellular Therapeutics (NYSEAMERICAN IMUC) Insider Trading and Institutional Ownership History

Insider Trading History for Immunocellular Therapeutics (NYSEAMERICAN:IMUC)

Immunocellular Therapeutics (NYSEAMERICAN IMUC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2015Andrew GengosCEOBuy10,000$0.44$4,400.00191,333View SEC Filing  
2/18/2015Andrew GengosCEOBuy41,333$0.60$24,799.80View SEC Filing  
2/18/2015Andrew GengosCEOBuy41,333$0.60$24,799.80View SEC Filing  
2/18/2015Anthony GringeriVPBuy30,000$0.60$18,000.00View SEC Filing  
2/18/2015David FractorVPBuy16,667$0.60$10,000.20View SEC Filing  
8/21/2014Anthony GringeriVPBuy11,000$0.91$10,010.00View SEC Filing  
8/14/2014Andrew GengosCEOBuy10,000$0.90$9,000.00View SEC Filing  
12/20/2013Gary TitusDirectorBuy18,000$0.78$14,040.0018,000View SEC Filing  
12/18/2013Andrew GengosCEOBuy27,000$0.72$19,440.0027,000View SEC Filing  
10/21/2013John S YuInsiderSell267,387$2.91$778,096.17View SEC Filing  
8/29/2013James BenderVPSell14,203$2.87$40,762.61100View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immunocellular Therapeutics (NYSEAMERICAN IMUC) News Headlines

Source:
DateHeadline
Form 8-K ImmunoCellular Therapeut For: May 14Form 8-K ImmunoCellular Therapeut For: May 14
www.streetinsider.com - May 16 at 5:34 PM
Immunocellular Therapeutics (IMUC) Posts Quarterly  Earnings ResultsImmunocellular Therapeutics (IMUC) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 15 at 9:46 AM
ImmunoCellular Therapeutics Announces First Quarter 2018 Financial ResultsImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 14 at 5:15 PM
Short Interest in Immunocellular Therapeutics (IMUC) Declines By 1.5%Short Interest in Immunocellular Therapeutics (IMUC) Declines By 1.5%
www.americanbankingnews.com - May 10 at 1:20 AM
ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Up 5.3% in AprilImmunoCellular Therapeutics Ltd (IMUC) Short Interest Up 5.3% in April
www.americanbankingnews.com - April 24 at 6:38 PM
Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell ProgramBlog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program
finance.yahoo.com - April 16 at 8:22 AM
BRIEF-Immunocellular Therapeutics Announces Achievement Of Next Key Milestone In Stem-To-T-Cell Research ...BRIEF-Immunocellular Therapeutics Announces Achievement Of Next Key Milestone In Stem-To-T-Cell Research ...
www.reuters.com - April 13 at 5:26 PM
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno ...ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno ...
www.prnewswire.com - April 13 at 5:26 PM
ImmunoCellular advances Stem-to-T-Cell technology; shares up 27% premarketImmunoCellular advances Stem-to-T-Cell technology; shares up 27% premarket
seekingalpha.com - April 12 at 8:49 AM
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology ProgramImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
finance.yahoo.com - April 12 at 8:49 AM
ImmunoCellular Therapeutics Ltd (IMUC) Sees Significant Growth in Short InterestImmunoCellular Therapeutics Ltd (IMUC) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 10 at 6:34 PM
ImmunoCellular Therapeutics (IMUC) Receives Going Concern Opinion from AuditorImmunoCellular Therapeutics (IMUC) Receives 'Going Concern' Opinion from Auditor
www.streetinsider.com - March 28 at 8:35 AM
ImmunoCellular Therapeutics Ltd (IMUC) Short Interest UpdateImmunoCellular Therapeutics Ltd (IMUC) Short Interest Update
www.americanbankingnews.com - March 26 at 6:52 PM
ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern ExplanationImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation
finance.yahoo.com - March 26 at 8:29 AM
Edited Transcript of IMUC earnings conference call or presentation 13-Mar-18 9:00pm GMTEdited Transcript of IMUC earnings conference call or presentation 13-Mar-18 9:00pm GMT
finance.yahoo.com - March 18 at 8:24 AM
ImmunoCellular Therapeutics Announces Fourth Quarter and Full ... - PR Newswire (press release)ImmunoCellular Therapeutics Announces Fourth Quarter and Full ... - PR Newswire (press release)
www.prnewswire.com - March 14 at 8:44 AM
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 13 at 7:12 PM
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
finance.yahoo.com - March 7 at 8:25 AM
Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum PharmaceuticalsToday’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum Pharmaceuticals
finance.yahoo.com - March 7 at 8:25 AM
Consolidated Research: 2018 Summary Expectations for Peoples United Financial, American International Group, ImmunoCellular Therapeutics, W&T Offshore, ONEOK, and Avon Products — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for People's United Financial, American International Group, ImmunoCellular Therapeutics, W&T Offshore, ONEOK, and Avon Products — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - March 6 at 8:22 AM
Short Interest in ImmunoCellular Therapeutics Ltd (IMUC) Rises By 26.0%Short Interest in ImmunoCellular Therapeutics Ltd (IMUC) Rises By 26.0%
www.americanbankingnews.com - February 27 at 6:00 PM
ImmunoCellular Therapeutics Announces Review of Strategic Alternatives - PR Newswire (press release)ImmunoCellular Therapeutics Announces Review of Strategic Alternatives - PR Newswire (press release)
www.prnewswire.com - February 24 at 8:23 AM
ImmunoCellular Therapeutics (IMUC) to Review Strategic Alternatives - StreetInsider.comImmunoCellular Therapeutics (IMUC) to Review Strategic Alternatives - StreetInsider.com
www.streetinsider.com - February 23 at 8:31 AM
ImmunoCellular Therapeutics Announces Review of Strategic AlternativesImmunoCellular Therapeutics Announces Review of Strategic Alternatives
finance.yahoo.com - February 22 at 8:28 AM
2 Medical Stocks Trending on Todays News2 Medical Stocks Trending on Today's News
finance.yahoo.com - February 13 at 3:48 PM
BRIEF-ImmunoCellular Therapeutics Ended 2017 With About $6.6 Mln In CashBRIEF-ImmunoCellular Therapeutics Ended 2017 With About $6.6 Mln In Cash
www.reuters.com - February 13 at 9:56 AM
ImmunoCellular Therapeutics Announces Update on Financial ConditionImmunoCellular Therapeutics Announces Update on Financial Condition
finance.yahoo.com - February 13 at 9:56 AM
Short Interest in ImmunoCellular Therapeutics Ltd (IMUC) Drops By 2.9%Short Interest in ImmunoCellular Therapeutics Ltd (IMUC) Drops By 2.9%
www.americanbankingnews.com - January 25 at 1:10 AM
ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Down 7.1% in DecemberImmunoCellular Therapeutics Ltd (IMUC) Short Interest Down 7.1% in December
www.americanbankingnews.com - January 11 at 2:36 AM
ImmunoCellular Therapeutics Ltd (IMUC) Short Interest Up 46.5% in DecemberImmunoCellular Therapeutics Ltd (IMUC) Short Interest Up 46.5% in December
www.americanbankingnews.com - December 27 at 6:40 PM
Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus PharmaceuticalsToday’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals
finance.yahoo.com - December 15 at 9:05 AM
ImmunoCellular Therapeutics (IMUC) Says it Achieved Key Milestone in Stem-to-T-Cell Research Immuno-Oncology ProgramImmunoCellular Therapeutics (IMUC) Says it Achieved Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
www.streetinsider.com - December 14 at 3:24 PM
ImmunoCellular Therapeutics +158% on immuno-oncology milestone - Seeking AlphaImmunoCellular Therapeutics +158% on immuno-oncology milestone - Seeking Alpha
seekingalpha.com - December 14 at 7:49 AM
ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology ProgramImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
finance.yahoo.com - December 13 at 4:22 PM
Edited Transcript of IMUC earnings conference call or presentation 21-Nov-17 10:00pm GMTEdited Transcript of IMUC earnings conference call or presentation 21-Nov-17 10:00pm GMT
finance.yahoo.com - November 28 at 3:23 PM
ImmunoCellular Therapeutics Ltd (IMUC) Sees Large Increase in Short InterestImmunoCellular Therapeutics Ltd (IMUC) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 28 at 1:04 AM
ImmunoCellular Therapeutics (IMUC) CEO Anthony Gringeri on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaImmunoCellular Therapeutics' (IMUC) CEO Anthony Gringeri on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 23 at 2:19 AM
ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017
finance.yahoo.com - November 23 at 2:19 AM
ImmunoCellular Therapeutics, Ltd. to Host Earnings CallImmunoCellular Therapeutics, Ltd. to Host Earnings Call
finance.yahoo.com - November 21 at 8:05 PM
ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial ResultsImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 21 at 8:04 PM
ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017 - PR Newswire (press release)ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017 - PR Newswire (press release)
www.prnewswire.com - November 17 at 6:33 AM
ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017
finance.yahoo.com - November 17 at 6:33 AM

SEC Filings

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Immunocellular Therapeutics (NYSEAMERICAN IMUC) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.